Royalty Pharma
Finance · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
110 E 59th St Fl 33, New York, New York,...Phone Number
(212) 883-0200Website
www.royaltypharma.comRevenue
$2.5 BillionStock Symbol
RPRXIndustry
ZI Rank: 5
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
6
4
5
6
5
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Johnson & Johnsons' TremfyRead more
Royalty Pharma Org Chart
Get the full picture
Sign in to uncover key details.
MU
Head Executive VP, Research & Investments
DM
Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Royalty Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Royalty Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Royalty Pharma has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Royalty Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Royalty Pharma
Click to see if Royalty Pharma had a recent Job posting/layoffs
Earning: See what the market has to say on Royalty Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Royalty Pharma has new funding data
Check out if Royalty Pharma is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Royalty Pharma
Compare insights from companies similar to Royalty Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Royalty Pharma is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Royalty Pharma is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Royalty Pharma.
Royalty Pharma financials insights
Gather financial insights about Royalty Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Debt
$2B
Royalty Pharma Tech Stack
A closer look at the technologies used by Royalty Pharma
See more technologies
Most Recent Scoops
Earnings
Royalty Pharma has reported that its development stage pipeline has grown from 3 potential therapies at its IPO in June 2020 to 19 today, with peak royalty potential increasing by more than 30-fold over the period and peak potential royalties from its late-stage pipeline now totaling approximately $2 billion, alongside a regulatory approval success rate of approximately 90%.
IPO, Product Development, Pharmaceuticals, Finance
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Earnings, Finance
Person-Based
Earnings, Finance
Earnings
Business Finance, Finance, Financing & Debt
Royalty Pharma News & Media
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, anRoyalty Pharma (RPRX) Bets $100M On A Blood Disorder Breakthrough
On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental treatment for a rare blood disorder called polycythemia vera. It is Royalty Pharma’s second collaboration with Zealand, and it arrives just as rusfertide awaits a decision from the FDA. For a company […]Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?
In the life sciences sector, capital allocation often tells a clearer story than pure drug discovery. While pharmaceutical giants spend billions to develop and commercialize late-stage therapies, specialized royalty acquirers deploy targeted capital to harvest the long-term cash flows generated by those same drugs. A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a […]Zealand cashes out rusfertide royalty for USD 100m ahead of FDA decision - AllSci
Zealand Pharma converts rusfertide royalty to Royalty Pharma for $100M ahead of FDA decision. Discover the strategic financial move.
Read more news
Top Finance Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Royalty Pharma
Sign Up For FreeTo access detailed company insights
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. R... Read More
